Uloga angiogeneze u patogenezi metastaziranja (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Uloga angiogeneze u patogenezi metastaziranja" in Serbian language version.

refsWebsite

Global rank Serbian rank

6nih.gov

4^th place

8^th place

4doi.org

2^nd place

4^th place

1harvard.edu

18^th place

28^th place

doi.org

Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Shinkaruk, S.; Bayle, M.; Laïn, G.; Déléris, G. (март 2003). „Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy”. Curr Med Chem Anticancer Agents. 3 (2): 95—117. PMID 12678905. doi:10.2174/1568011033353452. .
Hoff PM, Machado KK. Role of angiogenesis in the pathogenesis of cancer. Hoff, P. M.; Machado, K. K. (новембар 2012). „Role of angiogenesis in the pathogenesis of cancer”. Cancer Treat Rev. 38 (7): 825—33. PMID 22677191. doi:10.1016/j.ctrv.2012.04.006. .
Elleman CJ, Eidinger D. Elleman, C. J.; Eidinger, D. (1977). „Suppressive factors in ascitic fluids and sera of mice bearing ascites tumors”. J Natl Cancer Inst. 59 (3): 925—31. PMID 894749. doi:10.1093/jnci/59.3.925. .
Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Holmgren, L.; O'Reilly, M. S.; Folkman, J. (1995). „Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression”. Nature Med. 1 (2): 149—53. PMID 7585012. doi:10.1038/nm0295-149. .

harvard.edu

adsabs.harvard.edu

Bashford EF, Murray JA, Cramer W. Bashford, E. F.; Murray, J. A.; Cramer, W. (1907). „The natural and induced resistance of mice to the growth of cancer”. Proc R Soc Lond. 79 (530): 164—87. Bibcode:1907RSPSB..79..164B. .

nih.gov

ncbi.nlm.nih.gov

Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995). „Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”. Am J Pathol. 146 (5): 1029—39. PMC 1869291 . PMID 7538264. .
Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Weidner, N. (1995). „Intratumor microvessel density as a prognostic factor in cancer”. Am J Pathol. 147 (1): 9—19. PMC 1869874 . PMID 7541613. .
Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Shinkaruk, S.; Bayle, M.; Laïn, G.; Déléris, G. (март 2003). „Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy”. Curr Med Chem Anticancer Agents. 3 (2): 95—117. PMID 12678905. doi:10.2174/1568011033353452. .
Hoff PM, Machado KK. Role of angiogenesis in the pathogenesis of cancer. Hoff, P. M.; Machado, K. K. (новембар 2012). „Role of angiogenesis in the pathogenesis of cancer”. Cancer Treat Rev. 38 (7): 825—33. PMID 22677191. doi:10.1016/j.ctrv.2012.04.006. .
Elleman CJ, Eidinger D. Elleman, C. J.; Eidinger, D. (1977). „Suppressive factors in ascitic fluids and sera of mice bearing ascites tumors”. J Natl Cancer Inst. 59 (3): 925—31. PMID 894749. doi:10.1093/jnci/59.3.925. .
Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Holmgren, L.; O'Reilly, M. S.; Folkman, J. (1995). „Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression”. Nature Med. 1 (2): 149—53. PMID 7585012. doi:10.1038/nm0295-149. .